What Happened? A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and MRNA and see which is better for you.

The biotech’s licensing pact with Pfizer, revealed last week, will leverage its adjuvant vaccine platform in the development of two undisclosed Pfizer products. After pocketing ...

Novavax (NVAX) closed at $8.97 in the latest trading session, marking a +2.51% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.01%. Meanwhile, the Dow ...

Shares of Novavax Inc. NVAX slipped 6.13% to $8.42 Thursday, on what proved to be an all-around dismal trading session for ...

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the ...

A webcast of the presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. SOURCE Novavax, ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share in the year-ago period. The consensus estimate for Pfizer's quarterly ...

Shares of Novavax Inc. NVAX slid 1.19% to $8.27 Wednesday, on what proved to be an all-around mixed trading session for the ...